Imatinib Mesylate and Temozolomide in Treating Patients With Malignant Glioma
Status:
Completed
Trial end date:
2008-11-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Imatinib mesylate may stop the growth of tumor cells by blocking some of the
enzymes needed for cell growth. Drugs used in chemotherapy, such as temozolomide, work in
different ways to stop the growth of tumor cells, either by killing the cells or by stopping
them from dividing. Giving imatinib mesylate together with temozolomide may kill more tumor
cells.
PURPOSE: This phase I trial is studying the side effects and best dose of imatinib mesylate
when given together with temozolomide in treating patients with malignant glioma.